The research was published in JAMA Ophthalmology in July 2024
Summary of GLP1 adoption trends in Europe GLP1 uptake in Europe remains far lower than US levels Consumer scepticism across Europe limits weightloss drug use despite rising awareness Public healthcare coverage constraints slow adoption compared with commercially driven US Even optimistic scenarios predict only modest calorieintake reductions across Europe Gradual destigmatisation suggests slow growth but limited longterm market disruption GLP-1 receptor agonists have seen far greater traction in the US than in Europe
One issue some people may run into is that they have a limited dietary intake or specific medical conditions that may affect L-carnitine levels in the body, causing a deficiency that could cause them to consider supplements like liquid carnitine
The letters O and I are omitted to prevent confusion with numbers 0 and 1 There are Two Types of Codes - Stem Codes for Clinical entities that can be assigned alone and Extension Codes for adding more detail to the Stem Code
These indicate discharge rates relative to capacity
However, the barriers to oral drug delivery (such as the solubility and dissolution, absorption, presystemic metabolism, and excretion) cannot be ignored too
